Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the fourth quarter of 2023.
- Total revenue increased 8% annually to $1.60 billion in Q4, both on a reported basis and excluding the impact of foreign currency
- Women’s Health revenue increased 7% year-over-year, driven primarily by strong growth in Organon’s fertility products
- Biosimilar revenue jumped 49% from last year as reported, and 48% on an FX-adjusted basis in Q4
- Established Brands revenue rose 3%, despite the impacts of Volume-Based Procurement initiatives and a challenging operating environment in China
- Q4 net income more than doubled to $546 million or $2.13 per share in the three months ended December 2023
- On an adjusted basis, earnings moved up to $0.88 per share in Q4 from $0.81 per share last year
- At $449 million, fourth-quarter adjusted EBITDA was up 18% from the year-ago quarter.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key metrics from Kroger’s (KR) Q3 2025 earnings results
The Kroger Co. (NYSE: KR) reported its third quarter 2025 earnings results today. Total company sales rose to $33.9 billion from $33.6 billion in the same period last year. Identical
Dollar General (DG) Q3 2025 Earnings: Key financials and quarterly highlights
Dollar General Corporation (NYSE: DG) reported its third quarter 2025 earnings results today. Net sales increased 4.6% year-over-year to $10.65 billion. Same-store sales increased 2.5%. Net income was $282.7 million, or
HRL Earnings: All you need to know about Hormel Foods’ Q4 2025 earnings results
Hormel Foods Corporation (NYSE: HRL) reported its fourth quarter 2025 earnings results today. Net sales increased 1.5% year-over-year to $3.18 billion. Organic sales were up 2%. Net loss attributable to Hormel
